1. Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement 2018;14:367–429.
4. Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 2015;36:297–309.
5. McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009;50:348–55.
6. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834–40.
9. Kang Y, Na D, Hahn S. Seoul neuropsychological screening battery. Incheon (KR): Human brain research & consulting Co.; 2003.
10. Cho SH, Choe YS, Kim YJ, Kim HJ, Jang H, Kim Y, et al. Head-to-head comparison of F-florbetaben and Fflutemetamol in the cortical and striatal regions. J Alzheimers Dis 2020;76:281–90.
12. Farrar G. Regional visual read inspection of [F] flutemetamol brain images from end-of-life and amnestic MCI subjects. J Nucl Med 2017;58(Suppl 1):1250.
14. Kim HJ, Cho H, Werring DJ, Jang YK, Kim YJ, Lee JS, et al. F-AV-1451 PET imaging in three patients with probable cerebral amyloid angiopathy. J Alzheimers Dis 2017;57:711–6.
15. Martinez G, Flicker L, Vernooij RW, Fuentes Padilla P, Zamora J, Roque i Figuls M, et al. F-18 PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2016 (5):CD012216.
16. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273–89.
17. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015;11:1–15.
18. Park JH, Seo SW, Kim C, Kim SH, Kim GH, Kim ST, et al. Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol Aging 2014;35:254–60.
19. Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 2012;59:1152–60.
21. Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010;74:121–7.
22. De Santi S, Catafau A, Seibyl J, Bullich S. Robustness of F-Florbetaben SUVR cutoff quantification across reference regions and standards of truth. J Nucl Med 2016;57(Suppl 2):458.